Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol Injection Dose-response in CKD with SHPT
NCT00667576Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Apr 2008
- Primary completion
- Mar 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of paricalcitol in secondary hyperparathyroidism (SHPT), sponsored by Abbott Laboratories. Started Apr 2008; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00667576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667576.